Blood Adv. 2026 Nov 20. pii: bloodadvances.2026020796. [Epub ahead of print]
Yi Zhang,
Huafeng Wang,
Wenwen Wei,
Dandan Zhao,
Jie Sun,
Yongfang Xu,
Fang Chen,
Wanhong Xu,
Xiaoying Zhang,
Long Mao,
Can Jin,
Xueying Yang,
Xiao Xu,
Guido Marcucci,
Bin Zhang,
Jie Jin.
FLT3 mutations presented in 30% of acute myeloid leukemia (AML) patients and correlate with high relapse rates and poor prognosis. Resistance mutations and central nervous system (CNS) involvement remain major challenges despite clinical FLT3 inhibitors. This study evaluated the preclinical efficacy and safety of STI-8591, a novel kinase inhibitor, in FLT3-mutant (FLT3 mut)AML, focusing on the FLT3-ITD-F691L resistance mutation and CNS leukemia models to support clinical translation. STI-8591 was tested in FLT3 mut human AML cell lines (MV4-11, MOLM-13), murine Ba/F3 cells expressing various FLT3 mutants (D835Y, ITD-D835Y, ITD-F691L), and primary AML blasts. Effects on proliferation, apoptosis, cell cycle, colony formation, and FLT3 signaling were assessed. Five in vivo models were used: Ba/F3-FLT3 mutant xenograft, MllPTD/WT:Flt3ITD/ITD transgenic, MOLM-13 CDX, CNS leukemia CDX, and chemoresistant PDX models. Pharmacokinetics and toxicology were evaluated in mice, rats, and dogs. In vitro, STI-8591 potently inhibited proliferation of FLT3 mut cell lines (IC50: 1.94-10.82 nM) and primary blasts (de novo IC50: 3.37-160.50 nM; relapsed/refractory IC50: 12.4-800.3 nM), induced G0/G1 arrest and apoptosis, and blocked FLT3/STAT5/AKT/ERK phosphorylation. In patient-derived CD34⁺blasts, 40 nM STI-8591 reduced colony formation by 94%. Orally administered STI-8591 (3-30 mg/kg) significantly suppressed leukemia progression and prolonged survival in all models. Notably, it maintained efficacy against the FLT3-ITD-F691L gatekeeper mutation, outperforming Gilteritinib, and showed activity in CNS leukemia and chemoresistant PDX models. PK/toxicology studies demonstrated favorable profiles without unexpected adverse effects. STI-8591 is a promising therapeutic agent for FLT3 mut AML, including resistant subtypes and CNS involvement.